secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revium Rx. (RVRC)
CIK:        0001839140
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001213900-26-045633
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revium Rx appoints Amir Avraham permanent CEO, Shlomi Schwartzblat as Chairman
------------------------------------------------------------------------------

- Appointed Amir Avraham as permanent CEO (was interim since May 2025), effective Feb 1, 2026.
- Monthly salary of NIS 55,000; eligible for annual discretionary bonus and one-time $50,000 bonus if $5M equity raised within 18 months.
- Option grant of 1,300,000 shares vesting from Feb 1, 2026; additional 300,000 upon $3M investments, and 300,000 upon M&A completion.
- Appointed Shlomi Schwartzblat as Director and Chairman of the Board, effective immediately, term through 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1839140/000121390026045633/0001213900-26-045633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1839140/000121390026045633/ea0287042-8k_revium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-045633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer